Moran Wealth Management LLC Has $4.66 Million Position in Medpace Holdings, Inc. $MEDP

Moran Wealth Management LLC lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 14,854 shares of the company’s stock after selling 2,074 shares during the period. Moran Wealth Management LLC’s holdings in Medpace were worth $4,662,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock worth $94,000 after purchasing an additional 83 shares during the last quarter. Inspire Investing LLC bought a new stake in shares of Medpace during the first quarter worth $2,059,000. Truist Financial Corp grew its holdings in shares of Medpace by 10.2% during the second quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock worth $4,048,000 after purchasing an additional 1,197 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Medpace by 10.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company’s stock worth $371,000 after purchasing an additional 111 shares during the last quarter. Finally, Voya Investment Management LLC grew its holdings in shares of Medpace by 7.6% during the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company’s stock worth $6,696,000 after purchasing an additional 1,560 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. William Blair restated a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Truist Financial increased their target price on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Mizuho raised their price target on Medpace from $328.00 to $510.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Cowen cut Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Finally, Barclays raised their price target on Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $424.10.

Medpace Stock Down 2.0%

Medpace stock opened at $516.93 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15. The business’s 50-day simple moving average is $486.83 and its 200 day simple moving average is $377.81. The stock has a market cap of $14.52 billion, a price-to-earnings ratio of 38.43, a P/E/G ratio of 3.31 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the prior year, the firm posted $2.75 earnings per share. The company’s quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 48,487 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares of the company’s stock, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the transaction, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. The trade was a 14.81% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.